U.S. markets open in 3 hours 51 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
579.81+4.08 (+0.71%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close575.73
Bid0.00 x 1100
Ask590.00 x 800
Day's Range575.12 - 582.25
52 Week Range303.22 - 664.64
Avg. Volume861,900
Market Cap61.687B
Beta (5Y Monthly)0.50
PE Ratio (TTM)22.45
EPS (TTM)25.83
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est678.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
15% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Microsoft-Backed Databricks Plans IPO Next Year

    Microsoft-Backed Databricks Plans IPO Next Year

    (Bloomberg) -- Databricks Inc., whose business overlaps with data and analytics software maker Snowflake Inc., is preparing an initial public offering that could come in the first half of 2021, according to people with knowledge of the matter.Discussions are at an early stage and the company has held talks with banks but has yet to hire underwriters, said the people, who asked not to be identified discussing private information. The company’s plans could still change, they said.San Francisco-based Databricks is aiming to go public at a price significantly higher than the valuation in its last funding round, one of the people said. It was valued in 2019 at $6.2 billion when it raised $400 million, according to a statement at the time.A representative for Databricks declined to comment.Software is the most profitable segment of the IPO market for investors, according to data compiled by Bloomberg. Snowflake, which went public last month at a market value of $70 billion, has seen its shares double from its IPO price.Of the $129 billion raised in IPOs on U.S. exchanges this year, Software accounts for 10% of the total, the data show. That portion rises to more than 20% when special purpose acquisition companies are excluded. Software firms have also outperformed other newly public companies, rising 97% from their offer prices on a weighted average basis compared with 48% for other companies, the data show.Databricks has raised about $900 million from backers including Andreessen Horowitz, Coatue Management, New Enterprise Associates, Tiger Global Management, BlackRock Inc. and T. Rowe Price Group Inc. Its backers also include Battery Ventures, Sinewave Ventures, In-Q-Tel and Data Collective.Microsoft Corp. is both a Databricks investor and a partner, integrating a version of the startup’s software into its cloud product, Microsoft Azure.Databricks, founded in 2013, has more than 5,000 customers including Royal Dutch Shell Plc, Conde Nast International Inc. and Regeneron Pharmaceuticals, Inc., according to its website.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Barrons.com

    Remdesivir Gets FDA Approval. What It Means for Gilead Stock and Vaccine Makers.

    Until vaccines end the Covid pandemic, analysts expect billions of dollars in annual sales for treatments and other remedies.

  • Yahoo Finance Video

    Remdesivir ‘is not a knock out punch’ but it does help patients ‘recover quicker’: doctor

    Dr. Amesh Adalja, Johns Hopkins Center for Health Security, joins The Final Round to discuss his thoughts on the rising numbers of cases across the globe and the most recent developments in the vaccine race.